Immunic to Participate in Investor Conferences in November
PR Newswire•02/11/2026•06:30 ET
0
Key Highlights
- ➤IMUX schedules three November investor-conference appearances, including Guggenheim, Stifel, and Jefferies meetings
- ➤Progressive Multiple Sclerosis R&D Day set for November 5 with management and two MS experts
- ➤Vidofludimus calcium Phase 3 relapsing-MS top-line data expected by end of 2026
- ➤Additional Phase 3 progressive-MS trial expected to initiate later in 2026
Expert Statements
Jiwon Oh, M.D., Ph.D., FRCPC, Division of Neurology, University of Toronto
“The group will discuss the key unmet needs in progressive MS and the persistent needs for innovative approaches to the development of therapies that target novel mechanisms associated with neurodegeneration and MS progression.”
Maria Pia Sormani, Ph.D., University of Genoa, Italy
“The group will discuss the key unmet needs in progressive MS and the persistent needs for innovative approaches to the development of therapies that target novel mechanisms associated with neurodegeneration and MS progression.”
Immunic to Participate in Investor Conferences in November PR Newswire
NEW YORK, Nov. 2, 2026 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the following investor conferences in November:
Get started
Create a free account to read the full story.